Immunovia AB (STO:IMMNOV), a manufacturer of healthcare devices, reported on Thursday that additional, more detailed data from the optimisation study of IMMray PanCan-d will be presented at PancreasFest 2019, to be held 24-26 July 2019 in Pittsburgh, US.

PancreasFest 2019 is a major annual meeting of pancreas physicians and translational researchers.

According to the company, the results demonstrated that the IMMray PanCan-d signature together with CA19-9 generated ROC AUC-values of 0.97, 0.98 and 0.96 when differentiating PDAC (pancreatic cancer) vs non-PDAC symptomatic individuals, healthy controls and type II diabetes, respectively. Similar results were achieved for all stages of PDAC.

These results show conclusively that IMMray PanCan-d has the capacity to differentiate between symptomatic, non-PDAC individuals, including type II diabetes, and all different stages of PDAC, Immunovia said.

This study collected and tested 937 patient samples from 150 PDAC (stage I-IV), 570 non-PDAC symptomatic individuals and 217 healthy individuals using IMMray PanCan-d in combination with CA19-9 ELISA assay.

To minimise confounding, pre-analytical variables, all patient samples were collected and processed using the same standard operating procedures, stored at -80°C and tested within a year after collection. Data analysis was performed using Immunovia software algorithms and accuracies, SVM ROC AUC-values, were determined for the different groups.